dc.contributor.author | Ekinci, Zelal | |
dc.contributor.author | Bek, Kenan | |
dc.contributor.author | Aytaç, Mehmet Baha | |
dc.contributor.author | Karadenizli, Aynur | |
dc.contributor.author | Hançer, Veysel Sabri | |
dc.date.accessioned | 2016-09-07T12:18:15Z | |
dc.date.available | 2016-09-07T12:18:15Z | |
dc.date.issued | 2014 | |
dc.identifier.citation | Ekinci Z, Bek K, Aytaç MB, Karadenizli A, Hancer VS. Renal outcome with eculizumab in two diarrhea-associated hemolyticeuremic syndrome cases with severe neurologic involvement. Hong Kong Journal of Nephrology 2014; 16(2): 46-49. doi.org/10.1016/j.hkjn.2014.07.001 | en_US |
dc.identifier.issn | 1561-5413 | |
dc.identifier.uri | http://www.sciencedirect.com/science/article/pii/S1561541314000234 | en_US |
dc.identifier.uri | https://hdl.handle.net/11446/1093 | en_US |
dc.description | İstanbul Bilim Üniversitesi, Tıp Fakültesi. | en_US |
dc.description.abstract | The kidney and brain are the two target organs in patients with Shiga toxin-producing Escherichia coli-associated hemolytic–uremic syndrome (STEC-HUS). Activation of the alternative complement pathway occurs in patients with STEC-HUS. A monoclonal antibody (eculizumab) directed against C5 has been reported to be effective against severe neurologic involvement in patients with STEC-HUS. We report on two STEC-HUS children with severe neurologic involvement treated with eculizumab. Despite prompt resolution of initial neurologic findings upon treatment with eculizumab, proteinuria and hypertension persisted in these patients. The persistence of these two risk factors is particularly emphasized to discuss the long-term effects of eculizumab, especially on renal involvement. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.identifier.doi | 10.1016/j.hkjn.2014.07.001 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | children | en_US |
dc.subject | eculizumab | en_US |
dc.subject | neurologic involvement | en_US |
dc.subject | renal disease | en_US |
dc.subject | Shiga toxin-producing Escherichia coli-associated hemolytic–uremic syndrome | en_US |
dc.title | Renal outcome with eculizumab in two diarrhea-associated hemolyticeuremic syndrome cases with severe neurologic involvement | en_US |
dc.type | article | en_US |
dc.relation.journal | Hong Kong Journal of Nephrology | en_US |
dc.department | DBÜ, Tıp Fakültesi | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.volume | 16 | en_US |
dc.identifier.startpage | 46 | en_US |
dc.identifier.endpage | 49 | en_US |
dc.contributor.authorID | TR5191 | en_US |
dc.contributor.authorID | TR155908 | en_US |
dc.contributor.authorID | TR178747 | en_US |
dc.contributor.authorID | TR4118 | en_US |
dc.contributor.authorID | TR43513 | en_US |
dc.relation.publicationcategory | Belirsiz | en_US |